IPD. Sozo testing & device now standard of care- NCCN cancer treatment guidelines

It is proven beyond doubt —
IPD’s Sozo has already been fully validated.
And the development potentials are also great.

Sozo is the only fully approved testing device for accurate measurement of body fluids, and composition.
But for lymphedema notably , fully approved for, testing can not easily be substituted and also approved by any other company for reimbursement , within years.

Every test and medical device must undergo years of individual trials and studies and test validation.

This process takes not only years at minimum, & costs greatly, but decades of data and software development is not easily replicated.
Although many may try, with time , even -why would they.

The software is hugely important.
Aka similar to ResMed’s development pathway .

IPD’s ,Sozo bioimpedence spectroscopy test , only, & prescribed for ongoing testing monitoring - can detect lymphedema development very early.
**Early enough to prevent onset if Sozo is used as the test for lymphedema.

Sozo is now the compulsory required monitoring for lymphedema in cancer patients, who are at risk for development the condition due to irradiation or surgical management of their cancers near to, or of axial lymph nodes

Breast cancer patients are notably at risk.
And also urogenital cancer patients post- treatment, prostate, ovarian, kidney/renal and bladder cancer patients, & melanoma patients for instance .

Especially breast cancer survivor patients have been in focus for decades wrt lymphedema risk due to the significantly high prevalence of development of it , as an enduring affliction, post- cancer treatment.
And more & younger very functionally active and high performing women are getting breast cancer, receive treatment and get into recovery, only to then develop lymphedema as a terrible morbid condition.

Lymphedema needs to be managed every day of a persons life lives ongoing, very much restricting their social and physical lives forever onwards.
Specialised limb pressure garments needing to be worn daily, with help required to even put the pressure bandaging on and to then remove at nights for showering etc, at also very high costs per patient annually, + for the needed maintenance medical adjunctive care & monitoring and therapies.
Estimates are as high as $10000 for medical management per year per patient, in the US.

It is unacceptable also if lymphedema can be prevented.

All patients are warned of the risk.
Understanding this is terrible for any post- cancer survivor patient to have to endure — IPD Sozo is a simple device, beautifully easy testing within 30seconds, and has been through a long and big journey in development.
Sozo is well -beyond full approvals with the FDA and complete validation, and received medical treatment prescribing codes.

Sozo, IPD BIS is the standard of care for definitive accurate body fluids analysis.

Sozo, IPD has this year achieved reimbursement code status— provides very easy testing, has been available , but now to be expanded across the US as well as ongoing here in Australia and New Zealand ,and elsewhere , as the global standard of care.

With broad other application.
Esp for *Renal care and diagnoses & dialysis fluids true accurate measurement - recognised and approved for accurate renal fluids analysis.
IPD Sozo was utilised by AstraZeneca for their phase 3 global kidney failure trials, through recent years, as the definitive accurate measurement and quantifying of renal failure.

*Heart failure diagnosis is an enormous market.
Testing and analysis of muscle mass composition.
* Sarcopenia.

Right now- reimbursement by the US Medicare equivalents as well as the private health insurance providers is expanding, and should accelerate.
Provision of Sozo BIS testing and monitoring is now the duty of care & must be paid for.

The private insurers also have duty of care to provide this for post-cancer patients at risk now.

No longer can there be fluffing and be said that tape measuring of upper arms circumferences or axial limb measurements, for detecting of any onset of lymphedema, as being sufficient or really acceptable.
It is not accurate nor definitive, and an insult to cancer survivors now I believe, though they be grateful for monitoring and follow-up care.
This has been the battle IPD shareholders and all involved with IPD inc cancer treatment specialists with a duty of care to detect and manage lymphedema- have been through for years with Sozo till now. For not only validation and full approvals & becoming the standard of care for monitoring testing for lymphedema , but now also is required care with reimbursement from both public and private cancer care providers.

IPD’s Sozo can detect onset of lymphedema soon enough for best management— soon enough even to fully prevent lymphedema development, or immediately allow best definitive minimising management of the condition.

Every cancer patient wishes for this.
It is now so simple, should be available, and is medically negligent by the surgeons or hospital cancer treating facilities— if is not provided.

The private health insurers and /or Medicaid must progressively pay for the Sozo testing - as in IPD’s Sozo device,which is the only available but also the specified definitive test ,alone.

IPD, ImpediMed’s BIS device testing is now written in to effectively global cancer treatment guidelines , as medically. necessary.

This caught my eye today also -
https://www.sciencedirect.com/science/article/pii/S2666087323003496


Harm ongoing from cancer treatment— life limiting also.
Also literally.

Private health insurers and cancer care facilities , must at very least provide sensitive follow -on monitoring care for post treatment survivors, & pay for the treatment under medical reimbursement codes now.

It really is —almost the least that they can do.

Lymphadema is a morbid horrible affliction condition & can be PREVENTED, if is accurate early detection —
this is what IPD & Sozo gives and does.
Only IPD Sozo testing and device.

Bravo to all the specialists and scientists and clinical team people and hardworking staff and key people in ImpediMed, who worked so hard for this for many years, esp during the past decade.

Setbacks are always a given.
IPD shareholders endured much, a great majority of now steely holders who have held IPD through recent years well understand and believed it would be only a matter of time. It has been inevitable, as the standard of care, that ultimately private health insurers will need to and will pay for Sozo service and ongoing monitoring testing & care if required for lymphedema if develops
IPD, Sozo was -When, not If.

It was clear though still took some years longer for full commercialisation success with also now reimbursement code status now and inclusion in definitive cancer treatment guidelines or the ‘bible’ for cancer patients care. For ALL cancer patients post -treatment who are at risk for lymphedema.

The company and everyone involved more broadly with ImpediMed , have now achieved full payment for service beyond commercialisation of Sozo , with extensive broad data development and full validation IPD’s data.
This IP and data also seriously valuable and cannot be replicated.

Happy New Year upcoming to IPD holders , and an exciting year is ahead now reimbursement and full validation for Sozo in medical treatment is achieved , the company is transcending to being cash generating + with incredible growth possible.

The big winners being the cancer patient survivors! , and also their dedicated doctors and facilities where staff provide cancer care and treatment.

Thankyou to all posters for extensive sharing of research and progression in use for Sozo this year.